Black Rock Inc. Cyclacel Pharmaceuticals, Inc. Transaction History

Black Rock Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$6.1 - $7.15 $127,910 - $149,928	-20,969 Reduced 81.7%	4,697 $5,000
Q1 2022 May 12, 2022	SELL	$5.93 - $7.6 $7,311 - $9,370	-1,233 Reduced 4.58%	25,666 $78,000
Q4 2021 Feb 10, 2022	BUY	$6.04 - $8.03 $6,486 - $8,624	1,074 Added 4.16%	26,899 $105,000
Q3 2021 Nov 09, 2021	SELL	$8.02 - $11.0 $4,394 - $6,028	-548 Reduced 2.08%	25,825 $136,000
Q2 2021 Aug 11, 2021	BUY	$7.59 - $10.48 $200,171 - $276,389	26,373 New	26,373 $156,000

Ticker CYCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,539,200
Market Cap $7.9M
Description
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combin...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.